Items where Author is "Horakova, D."

Article

(2022) Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study. NEUROLOGY. E2401-E2412. ISSN 0028-3878 1526-632X J9 - NEUROLOGY

(2022) Confirmed disability progression as a marker of permanent disability in multiple sclerosis. EUROPEAN JOURNAL OF NEUROLOGY. pp. 2321-2334. ISSN 1351-5101 1468-1331 J9 - EUR J NEUROL

(2022) Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. NEUROLOGY. ISSN 0028-3878

(2022) Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. BMC MEDICAL RESEARCH METHODOLOGY. ISSN 1471-2288 J9 - BMC MED RES METHODOL

(2022) Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Mult Scler. p. 13524585221084577. ISSN 1352-4585

(2021) Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal. pp. 755-766. ISSN 1352-4585

(2021) Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology. E783-E797. ISSN 0028-3878

(2021) The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. Mult Scler Relat Disord. p. 103012. ISSN 2211-0348

(2019) Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. Jama-Journal of the American Medical Association. pp. 175-187. ISSN 0098-7484

(2019) Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. pp. 458-468. ISSN 1468-330X (Electronic) 0022-3050 (Linking)

(2018) Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis. Multiple Sclerosis Journal. pp. 135-137. ISSN 1352-4585

(2018) Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Multiple sclerosis (Houndmills, Basingstoke, England). pp. 642-652. ISSN 1477-0970 (Electronic) 1352-4585 (Linking)

(2017) Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal. pp. 266-276. ISSN 1352-4585

(2017) Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years. Multiple Sclerosis Journal. pp. 361-363. ISSN 1352-4585

(2017) Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 71-73. ISSN 1352-4585

(2017) Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain. pp. 2426-2443. ISSN 0006-8950

(2017) The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis. Multiple Sclerosis Journal. pp. 32-34. ISSN 1352-4585

(2016) Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry. pp. 1343-1349. ISSN 0022-3050

(2016) Individual response to disease modifying therapies: a global observational cohort study. Multiple Sclerosis Journal. pp. 358-360. ISSN 1352-4585

(2016) Long-term disability trajectories in primary progressivs MS patients - a latent class growth analysis. Multiple Sclerosis Journal. pp. 44-46. ISSN 1352-4585